Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Axsome Therapeutics (NASDAQ: AXSM) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 2:00 p.m. ET. The company said a live webcast will be available on its Investors "Webcasts & Presentations" page.
A replay will be available for approximately 30 days following the event. This is a standard investor conference presentation with no financial results or clinical data provided in this notice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows mixed peer action, with ABVX up 2.630000002682209% and CRSP down 0.7300000172108412%, indicating no clear sector-wide move tied to this conference notice.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Earnings date notice | Neutral | +1.9% | Announced date and call details for Q4 and full-year 2025 results. |
| Jan 15 | Phase 3 trial start | Positive | -1.6% | Initiated FORWARD Phase 3 trial of AXS-14 in fibromyalgia patients. |
| Jan 12 | Prelim revenue update | Positive | +4.4% | Reported strong preliminary 2025 net product revenue and growth for key brands. |
| Dec 31 | Priority Review granted | Positive | +22.8% | FDA accepted and granted Priority Review to sNDA for AXS-05 in AD agitation. |
| Dec 31 | Pre-NDA feedback | Positive | +22.8% | FDA pre-NDA meeting minutes supported planned AXS-12 NDA submission. |
AXSM has often shown positive price reactions to strong clinical and revenue updates, with one divergence on a Phase 3 trial initiation.
Recent news for Axsome highlights a mix of regulatory, clinical, and commercial milestones. On Dec 31, 2025, FDA Priority Review for AXS-05 and supportive pre-NDA feedback for AXS-12 each saw +22.75% moves. Preliminary 2025 revenue on Jan 12, 2026 with strong growth preceded a +4.39% reaction. A Phase 3 fibromyalgia trial initiation on Jan 15, 2026 coincided with a modest -1.62% move, while an earnings date announcement on Jan 27, 2026 saw a +1.9% gain. Today’s conference appearance fits within an active communications cadence.
Market Pulse Summary
This announcement highlights Axsome’s participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 2:00 p.m. ET, with a webcast replay available for 30 days. It follows recent FDA-related milestones and strong preliminary 2025 revenue disclosures, which previously coincided with notable price moves. Investors may focus on any incremental color about commercial performance, regulatory timelines, and pipeline strategy shared during the presentation relative to these earlier updates.
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 2:00 p.m. ET.
A live webcast of the presentation can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the event.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple early and late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
FAQ
When will Axsome Therapeutics (AXSM) present at the Oppenheimer conference in February 2026?
How can investors watch the Axsome (AXSM) presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?
Will a replay of the Axsome (AXSM) Oppenheimer presentation be available after February 25, 2026?
What content will Axsome Therapeutics (AXSM) cover during its Oppenheimer conference presentation?
Where is the Axsome (AXSM) webcast hosted and how long will it remain accessible after the Oppenheimer event?
